Improvement in symptoms and quality of life for advanced non-small-cell lung cancer patients receiving ZD1839 (“Iressa”) in IDEAL 2 [abstract 1167] - Natale,R.B.; Skarin,A.; Maddox,A-M. (Proc Am Soc Clin Oncol, 2002)